Clinical Trial Update: Study Using Xolair in Rush Multi Oral Immunotherapy in Multi Food Allergic Patients [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial using Xolair (omalizumab) in rush multi-oral immunotherapy for multi-food allergies has completed with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Food Allergy

Drugs mentioned

• Xolair (omalizumab)

Snippet

Sponsor: Stanford University | Conditions: Food Allergy | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2017-10-25